DCF
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
+13.6%
US · US
CVS.US latest organized financial period shows revenue grew +7.85% YoY and net income declined -61.68% YoY. Current price is about 82 USD, while the model base case is about 61.92 USD; the current price sits +32.4% versus the base case. The page shows both reported and adjusted views; valuation still defaults to reported figures, while adjusted figures help isolate structured one-time-item impact. This summary is intended for public-information research and model review.
Annual financial metrics with switchable views. · Unit: USD
Price date: 2026/04/29 · Updated: 2026/04/29 15:26
Hover each model row to inspect formulas and inputs.
+32.43%
Free cash flow, growth, discount rate, and terminal growth form an intrinsic value range.
+13.6%
Uses recent net income as an owner-earnings proxy and discounts scenario growth.
+80.7%
Solves the forward FCF growth rate implied by the current price.
Current price implies roughly -0.3% annualized FCF growth.
Estimates earnings power value without assuming growth.
+32.43%
Updated: 2026/04/29 15:26
Collapsed by default. Expand to inspect structured one-time items and adjusted figures without making them the primary page focus.
A positive amountAfterTax means the item increased reported net income; a negative value means it reduced reported net income. Adjusted net income = reported net income minus total after-tax impact. Valuation defaults to reported figures; adjusted figures are shown to observe one-time-item impact.
| Period | Item | Category | After-tax impact | Confidence |
|---|---|---|---|---|
| 2025/12/31 | Business sale gain/loss | Asset sale gain/loss | -186M USD | Medium |
| 2025/12/31 | Integration and restructuring costs | Restructuring | -92M USD | Medium |
| 2024/12/31 | Integration and restructuring costs | Restructuring | -384M USD | Medium |
| 2023/12/31 | Asset impairment | Impairment | -360M USD | Medium |
| 2023/12/31 | Integration and restructuring costs | Restructuring | -1B USD | Medium |
| 2022/12/31 | Other special charges | Other | -5B USD | Medium |
| 2022/12/31 | Special income/charges | Other | -7B USD | Medium |
| 2021/12/31 | Other special charges | Other | -357M USD | Medium |
| 2025/09/30 | Business sale gain/loss | Asset sale gain/loss | -186M USD | Medium |
| 2025/09/30 | Integration and restructuring costs | Restructuring | -100M USD | Medium |
| 2025/06/30 | Business sale gain/loss | Asset sale gain/loss | -186M USD | Medium |
| 2025/06/30 | Integration and restructuring costs | Restructuring | -80M USD | Medium |
| 2025/03/31 | Business sale gain/loss | Asset sale gain/loss | -186M USD | Medium |
| 2025/03/31 | Integration and restructuring costs | Restructuring | -36M USD | Medium |
| 2024/09/30 | Asset impairment | Impairment | -664M USD | Medium |
| 2024/09/30 | Integration and restructuring costs | Restructuring | -386M USD | Medium |
| 2024/06/30 | Integration and restructuring costs | Restructuring | -417M USD | Medium |
| 2024/03/31 | Integration and restructuring costs | Restructuring | -95M USD | Medium |
| Period | Type | Revenue | Net Income | Adjusted net income | Free Cash Flow | Diluted EPS | Adjusted EPS |
|---|---|---|---|---|---|---|---|
| 2025/12/31 | Annual | 402B USD | 2B USD | 2B USD | 8B USD | 1.39 | 1.61 |
| 2024/12/31 | Annual | 373B USD | 5B USD | 5B USD | 6B USD | 3.66 | 3.96 |
| 2023/12/31 | Annual | 358B USD | 8B USD | 10B USD | 10B USD | 6.47 | 7.64 |
| 2022/12/31 | Annual | 322B USD | 4B USD | 15B USD | 13B USD | 3.26 | 11.71 |
| 2021/12/31 | Annual | - | - | - | - | - | - |
Total revenue recognized in each fiscal year.
Adjusted close trend. Current price sample covers: 2025/04/16 - 2026/04/29.